
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings Inc demonstrated a strong financial recovery in the third quarter of 2025, reporting total revenues of $4.22 million, which marked a significant 105% increase from the previous quarter. The company's gross margins also showed improvement, rising to 60.3%, compared to 39.8% in the prior quarter, indicating enhanced operational efficiency. Moreover, the announcement of a non-binding merger agreement with Applied Digital Cloud suggests potential strategic growth opportunities, further contributing to a positive outlook for the company.
Bears say
Ekso Bionics Holdings Inc experienced a revenue miss in the prior quarter, attributed to two significant order delays in enterprise sales that collectively accounted for $1.5 million. In the third quarter of 2025, the company reported revenues of $4.23 million alongside a net loss of $0.54 per share, revealing only a marginal improvement compared to consensus estimates of $4.16 million in revenue and a higher net loss of $0.96 per share. These factors, combined with the management's decision to downgrade the stock rating to Neutral, underscore a negative outlook on the company's financial performance and growth potential.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares